A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes
FX8474 has a modest effect on glucose regulation and immune cell composition, warranting further investigation into its potential therapeutic applications.
Authors
- Aurelijus Burokas (ORCID: https://orcid.org/0000-0002-0364-3496)
- Alexei Belenky
- Maria Vilenchik (ORCID: https://orcid.org/0000-0002-7270-5523)
- Vytautas Baranauskas (ORCID: https://orcid.org/0000-0003-0106-8026)
- Olga Potapova (ORCID: https://orcid.org/0000-0003-4026-2403)
- Jan Aleksander Kraśko (ORCID: https://orcid.org/0000-0001-6395-3384)
- Jonas Mingaila (ORCID: https://orcid.org/0009-0006-5214-0189)
- Emilija Baltrukonytė
- Šarūnas Tumas
- Agnė Vaitkevičienė
- Laurynas Orla
- Roberta Pocevičiūtė
- Dina Berlina
Institutions
- Vilnius University (LT)
- Vilnius University of Applied Sciences (LT)
- Baltic Psychology and Management University College (LV)
- National Cancer Institute (LT)
- Vilnius College of Design (LT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fphar.2025.1657042
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00